Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Arbutus_Biopharma
|
| gptkbp:collaboratedWith |
gptkb:U.S._Department_of_Defense
gptkb:Alnylam_Pharmaceuticals |
| gptkbp:focusesOn |
oncology
treatments for viral diseases |
| gptkbp:founded |
2005
|
| gptkbp:founder |
Mark J. Murray
|
| gptkbp:fundedBy |
gptkb:U.S._Department_of_Defense
|
| gptkbp:headquartersLocation |
gptkb:Burnaby,_British_Columbia,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tekmira Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
TKM-Ebola
TKM-PLK1 |
| gptkbp:platform |
lipid nanoparticle (LNP) delivery
|
| gptkbp:publiclyTraded |
NASDAQ: ABUS
|
| gptkbp:renamed |
gptkb:Arbutus_Biopharma
|
| gptkbp:specializesIn |
RNA interference therapeutics
|
| gptkbp:website |
https://www.arbutusbio.com/
|
| gptkbp:bfsParent |
gptkb:Arbutus_Biopharma
|
| gptkbp:bfsLayer |
7
|